Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Novel Model to Predict Gastrointestinal Bleeding During Left Ventricular Assist Device Support.

Yin MY, Ruckel S, Kfoury AG, McKellar SH, Taleb I, Gilbert EM, Nativi-Nicolau J, Stehlik J, Reid BB, Koliopoulou A, Stoddard GJ, Fang JC, Drakos SG, Selzman CH, Wever-Pinzon O.

Circ Heart Fail. 2018 Nov;11(11):e005267. doi: 10.1161/CIRCHEARTFAILURE.118.005267.

PMID:
30571195
2.

Microvascular Loss and Diastolic Dysfunction in Severe Symptomatic Cardiac Allograft Vasculopathy.

Daud A, Xu D, Revelo MP, Shah Z, Drakos SG, Dranow E, Stoddard G, Kfoury AG, Hammond MEH, Nativi-Nicolau J, Alharethi R, Miller DV, Gilbert EM, Wever-Pinzon O, McKellar SH, Afshar K, Khan F, Fang JC, Selzman CH, Stehlik J.

Circ Heart Fail. 2018 Aug;11(8):e004759. doi: 10.1161/CIRCHEARTFAILURE.117.004759.

PMID:
30354559
3.

Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.

Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C; ATTR-ACT Study Investigators.

N Engl J Med. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689. Epub 2018 Aug 27.

PMID:
30145929
4.

Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types.

Nativi-Nicolau J, Maurer MS.

Curr Opin Cardiol. 2018 Sep;33(5):571-579. doi: 10.1097/HCO.0000000000000547.

PMID:
30015648
5.

Unmasking Early Wild-Type Transthyretin Amyloidosis Cardiomyopathy in a Patient With Refractory Atrial Fibrillation and Unremarkable Cardiac Imaging.

Varedi D, Kovacsovics T, Downs Kelly E, Abraham J, Cowley J, Barrell K, Revelo MP, Stehlik J, Drakos S, Marrouche N, Wilson B, Swanson EA, Fang J, Nativi-Nicolau J.

Circ Heart Fail. 2018 Jul;11(7):e004812. doi: 10.1161/CIRCHEARTFAILURE.117.004812. No abstract available.

PMID:
29921704
6.

Cardiac Rotational Mechanics As a Predictor of Myocardial Recovery in Heart Failure Patients Undergoing Chronic Mechanical Circulatory Support: A Pilot Study.

Bonios MJ, Koliopoulou A, Wever-Pinzon O, Taleb I, Stehlik J, Xu W, Wever-Pinzon J, Catino A, Kfoury AG, Horne BD, Nativi-Nicolau J, Adamopoulos SN, Fang JC, Selzman CH, Bax JJ, Drakos SG.

Circ Cardiovasc Imaging. 2018 Apr;11(4):e007117. doi: 10.1161/CIRCIMAGING.117.007117.

PMID:
29653930
7.

Metaboreceptor activation in heart failure with reduced ejection fraction: Linking cardiac and peripheral vascular haemodynamics.

Barrett-O'Keefe Z, Lee JF, Berbert A, Witman MAH, Nativi-Nicolau J, Stehlik J, Richardson RS, Wray DW.

Exp Physiol. 2018 Jun;103(6):807-818. doi: 10.1113/EP086948. Epub 2018 Apr 24.

PMID:
29603461
8.

Serum Transthyretin: Predictor of Amyloidosis Outcomes?

Nativi-Nicolau J.

Circ Heart Fail. 2018 Feb;11(2):e004802. doi: 10.1161/CIRCHEARTFAILURE.118.004802. No abstract available.

PMID:
29449369
9.

Implementation of Real-Time Assessment of Patient-Reported Outcomes in a Heart Failure Clinic: A Feasibility Study.

Stehlik J, Rodriguez-Correa C, Spertus JA, Biber J, Nativi-Nicolau J, Zickmund S, Steinberg BA, Peritz DC, Walker A, Hess J, Drakos SG, Kfoury AG, Fang JC, Selzman CH, Hess R.

J Card Fail. 2017 Nov;23(11):813-816. doi: 10.1016/j.cardfail.2017.09.009. Epub 2017 Oct 2.

PMID:
28982635
10.

Circulating Galectin-3 Levels Are Persistently Elevated After Heart Transplantation and Are Associated With Renal Dysfunction.

Grupper A, Nativi-Nicolau J, Maleszewski JJ, Geske JR, Kremers WK, Edwards BS, Kushwaha SS, Pereira NL.

JACC Heart Fail. 2016 Nov;4(11):847-856. doi: 10.1016/j.jchf.2016.06.010. Epub 2016 Sep 7.

11.

Evaluation of Novel Metrics of Symptom Relief in Acute Heart Failure: The Worst Symptom Score.

AbouEzzeddine OF, Wong YW, Mentz RJ, Raza SS, Nativi-Nicolau J, Kociol RD, McNulty SE, Anstrom KJ, Hernandez AF, Redfield MM; NHLBI Heart Failure Clinical Research Network.

J Card Fail. 2016 Nov;22(11):853-858. doi: 10.1016/j.cardfail.2015.12.015. Epub 2015 Dec 21.

12.

Immunologic effects of continuous-flow left ventricular assist devices before and after heart transplant.

Ko BS, Drakos S, Kfoury AG, Hurst D, Stoddard GJ, Willis CA, Delgado JC, Hammond EH, Gilbert EM, Alharethi R, Revelo MP, Nativi-Nicolau J, Reid BB, McKellar SH, Wever-Pinzon O, Miller DV, Eckels DD, Fang JC, Selzman CH, Stehlik J; Utah Transplant Affiliated Hospitals (U.T.A.H.) Cardiac Transplant Program.

J Heart Lung Transplant. 2016 Aug;35(8):1024-30. doi: 10.1016/j.healun.2016.05.001. Epub 2016 May 6.

PMID:
27316382
13.

Impaired skeletal muscle vasodilation during exercise in heart failure with preserved ejection fraction.

Lee JF, Barrett-O'Keefe Z, Nelson AD, Garten RS, Ryan JJ, Nativi-Nicolau JN, Richardson RS, Wray DW.

Int J Cardiol. 2016 May 15;211:14-21. doi: 10.1016/j.ijcard.2016.02.139. Epub 2016 Mar 2.

14.

ISHLT pathology antibody mediated rejection score correlates with increased risk of cardiovascular mortality: A retrospective validation analysis.

Hammond MEH, Revelo MP, Miller DV, Snow GL, Budge D, Stehlik J, Molina KM, Selzman CH, Drakos SG, Rami A A, Nativi-Nicolau JN, Reid BB, Kfoury AG.

J Heart Lung Transplant. 2016 Mar;35(3):320-325. doi: 10.1016/j.healun.2015.10.035. Epub 2015 Oct 30.

PMID:
26970471
15.

Elevated resting heart rate in heart transplant recipients: innocent bystander or adverse prognostic indicator?

Wachter SB, McCandless SP, Gilbert EM, Stoddard GJ, Kfoury AG, Reid BB, McKellar SH, Nativi-Nicolau J, Saidi A, Barney J, McCreath L, Koliopoulou A, Wright SE, Fang JC, Stehlik J, Selzman CH, Drakos SG.

Clin Transplant. 2015 Sep;29(9):829-34. doi: 10.1111/ctr.12587. Epub 2015 Jul 27.

PMID:
26171948
16.

Shortness of breath and cardiac conduction abnormality caused by infiltrative cardiomyopathy.

Suksaranjit P, Ryan JJ, Han FT, Nativi-Nicolau J, Revelo MP, Wilson BD.

Eur Heart J. 2015 Sep 1;36(33):2238. doi: 10.1093/eurheartj/ehv197. Epub 2015 May 28. No abstract available.

PMID:
26022004
17.

Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure).

AbouEzzeddine OF, Haines P, Stevens S, Nativi-Nicolau J, Felker GM, Borlaug BA, Chen HH, Tracy RP, Braunwald E, Redfield MM.

JACC Heart Fail. 2015 Mar;3(3):245-52. doi: 10.1016/j.jchf.2014.10.009.

18.

Hemodynamic responses to small muscle mass exercise in heart failure patients with reduced ejection fraction.

Barrett-O'Keefe Z, Lee JF, Berbert A, Witman MA, Nativi-Nicolau J, Stehlik J, Richardson RS, Wray DW.

Am J Physiol Heart Circ Physiol. 2014 Nov 15;307(10):H1512-20. doi: 10.1152/ajpheart.00527.2014. Epub 2014 Sep 26.

19.

Current therapeutic approach in heart failure with preserved ejection fraction.

Nativi-Nicolau J, Ryan JJ, Fang JC.

Heart Fail Clin. 2014 Jul;10(3):525-38. doi: 10.1016/j.hfc.2014.04.007. Review.

PMID:
24975914
20.

Pharmacologic therapies for acute cardiogenic shock.

Nativi-Nicolau J, Selzman CH, Fang JC, Stehlik J.

Curr Opin Cardiol. 2014 May;29(3):250-7. doi: 10.1097/HCO.0000000000000057. Review.

PMID:
24686400

Supplemental Content

Loading ...
Support Center